Burstein, B., Altobelli, K. K., Williams, K., Cannon, C. P., Pencina, M. J., Sniderman, A. D., & Thanassoulis, G. (2017). Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation, 136(19), 1860–1862. https://doi.org/10.1161/CIRCULATIONAHA.117.029102

Burstein, Barry, Kathleen K. Altobelli, Ken Williams, Christopher P. Cannon, Michael J. Pencina, Allan D. Sniderman, and George Thanassoulis. “Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.” Circulation 136, no. 19 (November 7, 2017): 1860–62. https://doi.org/10.1161/CIRCULATIONAHA.117.029102.

Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, et al. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation. 2017 Nov 7;136(19):1860–2.

Burstein, Barry, et al. “Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.” Circulation, vol. 136, no. 19, Nov. 2017, pp. 1860–62. Pubmed, doi:10.1161/CIRCULATIONAHA.117.029102.

Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis G. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation. 2017 Nov 7;136(19):1860–1862.